Trial Profile
A Phase 2, Multicenter, Open-label Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Activity of Azacitidine and to Compare Azacitidine to Historical Controls in Pediatric Subjects With Newly Diagnosed Advanced Myelodysplastic Syndrome or Juvenile Myelomonocytic Leukemia Before Hematopoietic Stem Cell Transplantation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Azacitidine (Primary)
- Indications Juvenile myelomonocytic leukaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- Sponsors Celgene Corporation
- 09 Jul 2019 Status changed from active, no longer recruiting to completed.
- 25 Jun 2019 This trial has been completed in Belgium and France, according to European Clinical Trials Database.
- 19 Jun 2019 This trial has been completed in Ireland, according to European Clinical Trials Database.